Industrifonden Life Science recruits Bita Sehat as Investment Manager



Industrifonden strengthens its Life Science investment team through the recruitment of Dr. Bita Sehat as Investment Manager. Bita brings over 10 years of scientific expertise in oncology as well as corporate experience from Europe and North America. Prior to joining Industrifonden, Bita Sehat held the position of Head of Business Development and Strategic Partnerships for Battat Inc., a consumer goods company. Her previous experience also includes positions in the health care team at Caisse de dépôt et placement du Québec, the Canadian investment fund, and Foster Rosenblatt Consulting, a forecasting and valuation firm in the pharmaceutical area.

Therapeutics remain the core of our business. The pharmaceutical industry is in the midst of an innovation leap, spearheaded by clinically meaningful novel therapies in areas such as oncology and immunology. Bita’s deep understanding for oncology combined with her North American business experience will be a great addition to our team, says Nina Rawal, Head of Life Science at Industrifonden.

Bita Sehat holds a Master of Science in Biomedicine and a Ph.D. in molecular oncology, both from Karolinska Institute. Her scientific experience also includes two post-doctoral fellowships at Karolinska Institute and McGill University, within the area of signal transduction in breast cancer. Bita also holds an MBA degree in Strategy and Business Valuation from Concordia University John Molson School of Business.

 I’m excited to join the talented life science team at Industrifonden. The Nordic life science landscape is highly innovative and I hope to utilize my scientific expertise and commercial experience to translate strong science into commercially viable products that can improve peoples’ lives, says Bita Sehat.

Industrifonden Life Science is one of the leading venture capital investors in the Nordics, with a focus on pharmaceuticals, medical devices and digital health. Current portfolio companies include Oncopeptides, Calliditas Therapeutics, and AMRA.